Xamic 500 mg (Capsule)
Medicine Details
| Category | Details |
|---|---|
| Generic | Tranexamic acid |
| Company | Renata limited |
| Also available as |
Title
Xamic - Tranexamic Acid Tablet
Categories
- Medicine
- Health & Wellness
Description
Xamic is a preparation of tranexamic acid, endowed with a strong antifibrinolytic action. It is used for the prophylaxis and therapy of various hemorrhagic manifestations in medicine, surgery, urology, obstetrics, otorhinolaryngology, stomatology, and oncology. The pharmacology of tranexamic acid includes its inhibition of plasminogen activation, low acute and chronic toxicity, well absorption by oral route, and absence of interference with clotting processes. It is available in doses suitable for adults, children, and elderly patients. Xamic has contraindications for individuals with known hypersensitivity, thromboembolic disease, serious kidney failure, and more. Its potential side effects include fatigue, conjunctival irritation, skin reactions, nausea, diarrhea, and rare cases of postural hypotension. It should not be administered during known and presumed pregnancy and lactation. Precautions include careful use in various conditions such as hyperfibrinolysis, renal insufficiency, urinary tract clots, and in individuals with cardiac or hepatic conditions. Xamic falls under the therapeutic classes of anti-fibrinolytic drugs and haemostatic drugs, and should be stored in a dry place at 15-30°C, away from light, and out of children's reach.
Attributes
- Indications:
- Prophylaxis and therapy of hemophtoes
- Digestive hemorrhages
- Hemorrhagic syndromes in leukaemia
- Cirrhosis and hemophilia
- Thrombocytopenic purpura
- Accidents during thrombolytic therapy and transfusion
- Prophylaxis and antihemorrhagic therapy during operations of any type and nature
- Prophylaxis and antihemorrhagic therapy of prostatic, vesical and renal surgery
- Prophylaxis and therapy of post-partum and puerperium hemorrhages
- Hemorrhagic metrophathies
- Functional menometrorrhagias
- To promote the formation of a fibrin capsule to wall off and thereby inhibit the growth of ovarian tumors
- To cause regression of ascites secondary to carcinoma
- To reduce bleeding during surgical interventions
- Pharmacology:
- Tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid) with strong antifibrinolytic action
- Inhibition of plasminogen activation
- Low acute and chronic toxicity
- Well absorption by oral route
- Lack of interference with clotting processes
- Dosage & Administration:
- Usual dose for adults: 500-1000 mg 3 times daily
- Mean recommended daily doses for prophylaxis: 0.5-1 gm orally and 500 mg by parenteral route
- Increased oral dose of 1-3 gm for therapy of hemorrhagic manifestations
- Prophylactic doses for children based on body weight
- No reduction in dosage for elderly patients unless evidence of renal failure
- Interaction:
- Incompatible with solutions containing penicillins
- Thrombolytic drugs like Streptokinase & Urokinase antagonise the antifibrinolytic action
- Increased potential for thrombus formation with concomitant administration of estrogen-containing drugs
- Contraindications:
- Known individual hypersensitivity
- Thromboembolic disease
- Arterial and venous thrombosis
- Endocavitary hemorrhages
- Serious kidney failure
- Side Effects:
- Fatigue
- Conjunctival irritation
- Nasal blockage
- Skin reddening
- Exanthems
- Nausea
- Diarrhea
- Postural hypotension
- Hypersensitivity reactions
- Pregnancy & Lactation:
- Tranexamic Acid should not be administered during known and presumed pregnancy
- Passes into breast milk to a concentration of approximately one hundredth of the concentration in the maternal blood
- Unlikely to have antifibrinolytic effect in the infant
- Precautions & Warnings:
- Use in cases of hyperfibrinolysis
- Prophylactic treatment to begin 24 hours before operation and continue until 3-4 days after
- Prolong therapy of hemorrhages for at least 24 hours after manifestations have disappeared
- Use with caution in renal dysfunctions, cardiopathic and hepatopathic subjects
- Therapeutic Class:
- Anti-fibrinolytic drugs
- Haemostatic drugs
- Storage Conditions:
- Store in a dry place at 15-30°C
- Away from light
- Keep out of children's reach